TOLERANZIA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.528 SEK | -1.49% |
|
-0.38% | +23.36% |
| 02-23 | Toleranzia AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| 02-23 | Toleranzia AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Toleranzia AB is a Sweden-based company engaged in the development of a platform technology for treatment of autoimmune diseases. The Company's main project is aimed against an autoimmune nerve-muscle disease and myasthenia gravis. The Companyâs platform technology enables the development of therapies targeting the cause of the disease, which in the current situation is the usual treatment.
Calendar
2024-05-19
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| +23.36% | 9.74M | |
| +5.87% | 32.95B | |
| +18.09% | 7.82B | |
| +32.81% | 4.17B | |
| -27.79% | 2.72B | |
| -32.48% | 1.15B | |
| +10.53% | 980M | |
| -36.79% | 873M | |
| -28.50% | 831M | |
| -15.67% | 688M |
- Stock Market
- Equities
- TOL Stock
- News Toleranzia AB
- Toleranzia Seeks SEK55 Million in Rights Offering; Stock Down